{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T14:56:22Z","timestamp":1770562582688,"version":"3.49.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The response to medications in children differs not only in comparison to adults but also between children of the different age groups and according to the disease. This is true for anti-infectives that are widely prescribed in children with malignancy. In the absence of pharmacokinetic\/pharmacodynamic paediatric studies, dosage is frequently based on protocols adapted to adults. After a short presentation of the drugs, we reviewed the population pharmacokinetic studies available for glycopeptides (vancomycin and teicoplanin, <jats:italic>n<\/jats:italic> = 5) and antifungals (voriconazole, posaconazole, and amphotericin B, <jats:italic>n<\/jats:italic> = 9) currently administered in children with onco-hematological malignancies. For each of them, we reported the main study characteristics including identified covariates affecting pharmacokinetics and proposed paediatric dosage recommendations. This review highlighted the very limited amount of data available, the lack of consensus regarding PK\/PD targets used for dosing optimization and regarding dosage recommendations when available. Additional PK studies are urgently needed in this specific patient population. In addition to pharmacokinetics, efficacy may be altered in immunocompromised patients and prospective clinical evaluation of new dosage regimen should be provided as they are missing in most cases.<\/jats:p>","DOI":"10.3389\/fphar.2021.635345","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T13:59:45Z","timestamp":1617285585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review"],"prefix":"10.3389","volume":"12","author":[{"given":"St\u00e9phanie","family":"Leroux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Mechinaud-Heloury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/aac.39.9.2042","article-title":"Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants","volume":"39","author":"Amantea","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","article-title":"Tips and traps analyzing pediatric PK data","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr. Anaesth."},{"key":"B3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","article-title":"Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients","volume":"33","author":"Anderson","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1128\/aac.47.4.1193-1199.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/aac.47.4.1179-1186.2003","article-title":"Minireview. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/AAC.40.3.609","article-title":"Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia","volume":"40","author":"Ayestar\u00e1n","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/archdischild-2017-314506","article-title":"Pharmacokinetic studies in children: recommendations for practice and research","volume":"103","author":"Baker","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40262-018-0658-1","article-title":"Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children","volume":"58","author":"Boonsathorn","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","article-title":"Population pharmacokinetic analysis of vancomycin in patients with haematological malignancies","volume":"49","author":"Buelga","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/myc.12899","article-title":"A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer","volume":"62","author":"Carlesse","year":"2019","journal-title":"Mycoses"},{"key":"B11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/00006454-199508000-00004","article-title":"Influence of malignancy on the pharmacokinetics of vancomycin in infants and children","volume":"14","author":"Chang","year":"1995","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/FTD.0b013e31823f3516","article-title":"Therapeutic drug monitoring of voriconazole in children","volume":"34","author":"Chen","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"B13","article-title":"Bioavailability and the variability of posaconazole exposure in healthy volunteers using a population pharmacokinetic analysis","author":"Chen","year":"2019","journal-title":"Popul. Approach Group Eur."},{"key":"B14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/bmj.39400.376424.BE","article-title":"Regulation of drugs for children in Europe","volume":"335","author":"Choonara","year":"2007","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/INF.0000000000001324","article-title":"Using prescription patterns in primary care to derive new quality indicators for childhood community antibiotic prescribing pediatr","volume":"35","author":"de Bie","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/00006454-199606000-00005","article-title":"Teicoplanin pharmacokinetics in pediatric patients","volume":"15","author":"Dufort","year":"1996","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B19","unstructured":"Guideline on the use of pharmacokinetics and 5 pharmacodynamics in the development of antibacterial medicinal products Committee for Human Medicinal Products2015"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ii5","DOI":"10.1093\/jac\/dki004","article-title":"Safety and efficacy of glycopeptide antibiotics","volume":"55","author":"Finch","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review","volume":"7","author":"Fisher","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fphar.2020.00552","article-title":"Population pharmacokinetics and dosage optimization of teicoplaninin children with different renal functions","volume":"11","author":"Gao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e01194","DOI":"10.1128\/AAC.01194-17","article-title":"Pharmacokinetic modeling of voriconazole to develop an alternative dosing regimen in children","volume":"62","author":"Gastine","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1574884712666170317161935","article-title":"Pediatric off-label and unlicensed drug use and its implications","volume":"12","author":"Gore","year":"2017","journal-title":"Curr. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FTD.0000000000000318","article-title":"Pediatric patients with solid or hematological tumor disease: vancomycin population pharmacokinetics and dosage optimization","volume":"38","author":"Guilhaumou","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"B29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/1078155215591386","article-title":"Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients","volume":"22","author":"Hadi","year":"2016","journal-title":"J. Oncol. Pharm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/FTD.0000000000000153","article-title":"Validation of a pediatric population pharmacokinetic model for vancomycin","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"B31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkz158","article-title":"Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants","volume":"74","author":"Jacqz-Aigrain","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B33","first-page":"146","article-title":"Liposomes and lipid structures as carriers of amphotericin B","volume":"9","author":"Janoff","year":"1990","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1078155211402107","article-title":"Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population","volume":"18","author":"Jarkowski","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/adc.2006.114835","article-title":"The problems in scaling adult drug doses to children","volume":"93","author":"Johnson","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1542\/peds.108.5.1089","article-title":"A survey of the use of off-label and unlicensed drugs in a Dutch children\u2019s hospital","volume":"108","author":"Jong","year":"2001","journal-title":"Pediatrics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","article-title":"Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance","volume":"38","author":"Keita","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"B40","first-page":"369","article-title":"Evaluation of pharmacokinetics and safety of liposomal amphotericin B (L-AMB) in patients with deep-seated fungal infection","volume":"61","author":"Kohno","year":"2013","journal-title":"Jpn. J. Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/08880019809014017","article-title":"Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients","volume":"15","author":"Krivoy","year":"1998","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1128\/aac.44.2.278-282.2000","article-title":"A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population antimicrobial agents","volume":"44","author":"Lamarre","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2141.2009.07844.x","article-title":"International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia","volume":"147","author":"Lehrnbecher","year":"2009","journal-title":"Br. J. Haematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"International pediatric fever and neutropenia guideline panel. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"TINN (treat infections in NeoNates) and GRiP (global research in paediatrics) consortiums. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"Leroux","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1128\/AAC.01427-16","article-title":"Population pharmacokinetics of liposomal amphotericin B in immunocompromised children","volume":"60","author":"Lestner","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"ofu006","DOI":"10.1093\/ofid\/ofu006","article-title":"Empiric vancomycin use in febrile neutropenic oncology patients","volume":"1","author":"Libuit","year":"2014","journal-title":"Open Forum Infect. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.clinthera.2019.04.027","article-title":"Model-based voriconazole dose optimization in Chinese adult patients with hematologic malignancies","volume":"41","author":"Liu","year":"2019","journal-title":"Clin. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1128\/AAC.40.5.1242","article-title":"Population pharmacokinetic study of teicoplanin in severely neutropenic patients","volume":"40","author":"Lortholary","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1023\/b:pham.0000048198.56873.d8","article-title":"Pharmacokinetics of teicoplanin in an ICU population of children and infants","volume":"21","author":"Lukas","year":"2004","journal-title":"Pharm. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","article-title":"Vancomycin: a review of population pharmacokinetic analyses","volume":"51","author":"Marsot","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40272-018-0295-z","article-title":"Vancomycin in pediatric patients with solid or hematological malignant disease: predictive performance of a population pharmacokinetic model and new optimized dosing regimens","volume":"20","author":"Marsot","year":"2018","journal-title":"Pediatr. Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1128\/aac.38.9.2041","article-title":"Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies","volume":"38","author":"Menichetti","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed Intralipid compared with conventional amphotericin B in neutropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1128\/AAC.04993-14","article-title":"Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects","volume":"59","author":"Muto","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000100013","article-title":"Amphotericin B dose optimization in children with malignant diseases","volume":"53","author":"Nath","year":"2007","journal-title":"Chemotherapy"},{"key":"B58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1046\/j.0306-5251.2001.01496.x","article-title":"Population pharmacokinetics of amphotericin B in children with malignant diseases","volume":"52","author":"Nath","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.dmpk.2015.08.003","article-title":"Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: population approach in Japanese pediatrics","volume":"30","author":"Ohata","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e01166","DOI":"10.1128\/AAC.01166-17","article-title":"Population pharmacokinetics of posaconazole tablets and Monte Carlo simulations to determine whether all patients should receive the same dose","volume":"61","author":"Petitcollin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/jac\/dks258","article-title":"Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients","volume":"67","author":"Pieper","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1128\/AAC.03685-14","article-title":"Population pharmacokinetics of teicoplanin in children","volume":"58","author":"Ramos-Mart\u00edn","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/jac\/39.6.789","article-title":"The pharmacokinetics of teicoplanin in infants and children","volume":"39","author":"Reed","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00431-014-2398-z","article-title":"Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines","volume":"174","author":"Ruggieri","year":"2015","journal-title":"Eur. J. Pediatr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jac\/44.3.407","article-title":"Teicoplanin pharmacokinetics in critically ill paediatric patients","volume":"44","author":"S\u00e1nchez","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e01477","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/MPH.0000000000000470","article-title":"Vancomycin therapeutic targets and nephrotoxicity in critically ill children with cancer","volume":"38","author":"Seixas","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40262-019-00735-7","article-title":"Voriconazole: a review of population pharmacokinetic analyses","volume":"58","author":"Shi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.ftd.0000249942.14145.ff","article-title":"Teicoplanin population pharmacokinetic analysis in hospitalized patients","volume":"28","author":"Soy","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/jac\/dkt176","article-title":"Age and gender-related differences in teicoplanin levels in paediatric patients","volume":"68","author":"Strenger","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jac\/21.suppl_a.47","article-title":"Pharmacokinetics of teicoplanin in children","volume":"21","author":"Tarral","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1128\/aac.32.8.1223","article-title":"Pharmacokinetics of teicoplanin in pediatric patients","volume":"32","author":"Terragna","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","article-title":"The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review","volume":"20","author":"Tkachuk","year":"2018","journal-title":"Paediatr. Drugs"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2014.02.003","article-title":"Global Research in Paediatrics. Paediatric drug development: the impact of evolving regulations","volume":"73","author":"Turner","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e02465","DOI":"10.1128\/AAC.02465-17","article-title":"A population pharmacokinetic model for a solid oral tablet formulation of posaconazole","volume":"62","author":"van Iersel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00228-012-1212-y","article-title":"Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myeloblastic syndrome","volume":"68","author":"Vehreschild","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group","volume":"340","author":"Walsh","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple- dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/00007691-200010000-00004","article-title":"Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients","volume":"22","author":"Wrishko","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"B83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/jpids\/pix022","article-title":"Voriconazole dosing in children younger than 3 yundergoing cancer chemotherapy or hematopoietic stem cell transplantation","volume":"7","author":"Yan","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"B84","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"B85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF02353784","article-title":"Population pharmacokinetics of teicoplanin in patients with endocarditis","volume":"23","author":"Yu","year":"1995","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1128\/AAC.02564-13","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/bcp.12710","article-title":"Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease","volume":"80","author":"Zhao","year":"2015","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.635345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T13:59:53Z","timestamp":1617285593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.635345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":87,"alternative-id":["10.3389\/fphar.2021.635345"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.635345","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"article-number":"635345"}}